# Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients

> **NCT02111031** · — · WITHDRAWN · sponsor: **Janssen Diagnostics, LLC**

## Conditions studied

- Metastatic Breast Cancer
- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02111031
- **Lead sponsor:** Janssen Diagnostics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The company decided not to start the study.
- **Last updated:** 2015-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111031, "Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02111031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*